Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity.

A positive correlation between the level of ICAM-1 in serum and the stage of neoplastic processes has been demonstrated. We studied ICAM-1 serum concentration in 27 colorectal cancer patients and investigated the effect of this molecule on cellular aggregation and toxicity. ICAM-1 serum concentration in the group of patients was significantly higher (P < 0.01) than in normal controls and was related to tumour stage. Patient sera inhibited both the formation of cellular aggregates and the percentage of specific lysis, the effect being lost when the serum was depleted of ICAM-1. These results suggest that the release of soluble ICAM-1 may represent a mechanism of tumour escape.

[1]  R. Rothlein,et al.  Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. , 1991, Cancer research.

[2]  M. Makgoba,et al.  Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders , 1991, The Lancet.

[3]  M. Parmar,et al.  A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC) , 1994 .

[4]  F. Herrmann,et al.  Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. , 1993, Leukemia.

[5]  R. Giavazzi,et al.  Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. , 1992, Cancer research.

[6]  B. Gallie,et al.  Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. , 1994, Oncogene.

[7]  H. Niitani,et al.  Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity. , 1992, Cancer research.

[8]  P. Selby,et al.  Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. , 1993, British Journal of Cancer.

[9]  N. King,et al.  Adherence status regulates the primary cellular activation responses to the flavivirus West Nile. , 1995, Immunology.

[10]  Y. Tomita,et al.  Expression of intercellular adhesion molecule‐1 (ICAM‐1) on renal‐cell cancer: Possible significance in host immune responses , 1990, International journal of cancer.

[11]  G. Cattoretti,et al.  CEA and NCA Expressed by Colon Carcinoma Cells Affect their Interaction with and Lysability by Activated Lymphocytes , 1992, The International journal of biological markers.

[12]  E. Aranda,et al.  Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). , 1991, British Journal of Cancer.

[13]  M. Maio,et al.  Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. , 1992, The New England journal of medicine.

[14]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[15]  H. Brady,et al.  Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. , 1992, American Journal of Physiology.

[16]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.

[17]  S. Koyama.  Immunosuppressive Effect of Shedding Intercellular Adhesion Molecule 1 Antigen on Cell‐mediated Cytotoxicity against Tumor Cells , 1994, Japanese journal of cancer research : Gann.

[18]  K. Havemann,et al.  Differential expression of the intercellular adhesion molecule-1 (ICAM-1) in lung cancer cell lines of various histological types. , 1993, European journal of cancer.

[19]  R. Rees,et al.  Interleukin-6 and tumour necrosis factor alpha synergistically block S-phase cell cycle and upregulate intercellular adhesion molecule-1 expression on MCF7 breast carcinoma cells. , 1993, Cancer letters.

[20]  N. Gualde,et al.  Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2. , 1992, Cellular immunology.

[21]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[22]  P. Reilly,et al.  The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1. , 1995, Journal of immunology.

[23]  J. Becker,et al.  Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. , 1993, Journal of Immunology.

[24]  M. Mizuno,et al.  Reinforced Cytotoxicity of Lymphokine‐activated Killer Cells toward Glioma Cells by Transfection of the Killer Cells with the γ‐Interferon Gene , 1995, Japanese journal of cancer research : Gann.

[25]  J. Izbicki,et al.  Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. , 1994, European journal of cancer.

[26]  M. Rubinstein,et al.  Interleukin-6 protects ductal breast carcinoma cells from MHC-unrestricted cell-mediated cytotoxicity. , 1992, Lymphokine and cytokine research.

[27]  J. Becker,et al.  Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.